Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAMINGO: Ninjin'yoeito for anorexia in frail patients with MCI or mild Alzheimer's disease
jRCTs071190011Completed
- Sponsor
- Tsumura & Co.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ninjinyoeito in Mild Cognitive Impairment (MCI), Alzheimer's disease (AD), mixed dementia and 4 more, sponsored by Tsumura & Co. Primary endpoint: Primary endpoint: Change in anorexia at 24 weeks. Started Aug 2019; status: completed.
02
Drugs
ninjinyoeito
03
Conditions
Mild Cognitive Impairment (MCI)Alzheimer's disease (AD)mixed dementiaFragilityanorexia nervosa (AN)
Beyond the preview
Go deeper on jRCTs071190011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071190011.